This Article Full Text Full Text (PDF) Supplemental Data Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Copyright Permission Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Cheng, T. Articles by Xu, J. Search for Related Content PubMed PubMed Citation Articles by Cheng, T. Articles by Xu, J.

Mutations within the TNF-Like Core Domain of RANKL Impair Osteoclast Differentiation and Activation

Molecular Orthopaedic Laboratory (T.C., N.J.P., C.W., J.W.-Y.T., M.-H.Z., J.X.), Centre for Orthopaedic Research, School of Surgery and Pathology, University of Western Australia, Nedlands, Western Australia 6009, Australia; and Department of Medicine (J.M.L., J.C.), University of Auckland, Auckland 1001, New Zealand

Address all correspondence and requests for reprints to: Jiake Xu, Molecular Orthopaedics Laboratory, Centre for Orthopaedic Research, School of Surgery and Pathology, University of Western Australia, Queen Elizabeth II Medical Centre, Second Floor M Block, Nedlands Western Australia 6009, Australia. E-mail: jiake.xu{at}uwa.edu.au.

Receptor activator of nuclear factor-B ligand (RANKL) is a key factor necessary for osteoclast differentiation and activation. Mutations within the TNF-like core domain of RANKL have been recently reported in patients with osteoclast-poor autosomal recessive osteopetrosis. However, the functional consequence owing to RANKL mutations has not been well characterized. Here we describe the functional propensity of RANKL mutants in osteoclast differentiation and their impact on RANKL-mediated signaling cascades. Recombinant RANKL (rRANKL) mutants within the TNF-like core domain exhibited diminished osteoclastogenic potential as compared with wild-type rRANKL1 encoding the full TNF-like core domain [amino acids (aa) 160–318]. Consistent with the insufficient activities on osteoclastogenesis, rRANKL mutants showed reduced activation of nuclear factor-B, IB degradation, and ERK phosphorylation. In addition, we found that rRANKL mutants interfered with wild-type rRANKL-induced osteoclastogenesis with deletion mutant rRANKL5 (aa 246–318) exhibiting the greatest inhibitory effect. The same mutant also significantly reduced wild-type rRANKL1 (aa 160–318)-induced osteoclastic bone resorption in vitro. BIAcore assays demonstrated that rRANKL5 alone, lacking the AA'' and CD loops, weakly binds to receptor activator of nuclear factor-B (RANK). Intriguingly, preincubation of mutant rRANKL5 with rRANKL1 before exposure to RANK enhanced the maximal binding level to RANK, indicating that rRANKL5 forms hybrid trimeric complexes with rRANKL1. Furthermore, RANKL mutant mimicking human RANKL V277 mutation in patients, impairs osteoclast differentiation and signaling. Taken together, these data lend support to the notion that the TNF-like core domain of RANKL contains structural determinants that are crucial for osteoclast differentiation and activation, thus providing a possible mechanistic explanation for the observed phenotype in osteopetrotic patients harboring RANKL mutations.